SCHEDULE: Vanguard Group Reports Zero Stake in Vir Biotechnology

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Vir Biotechnology Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to its Schedule 13G for Vir Biotechnology Inc. common stock.
• The filing reports 0% beneficial ownership of Vir Biotechnology Inc. common stock by The Vanguard Group.
• This change is attributed to an internal realignment within The Vanguard Group, which became effective on January 12, 2026.
• As a result of the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions, in accordance with SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects an internal organizational change at Vanguard and does not provide new information regarding Vir Biotechnology's operational or financial performance.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects an administrative change within a major institutional investor, The Vanguard Group, rather than a strategic investment decision regarding Vir Biotechnology Inc. Such internal realignments are not uncommon among large asset managers and typically do not signal a change in investment thesis for the underlying company, though they do alter the reported ownership structure.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders (Vir Biotechnology): The direct impact is minimal as the underlying holdings by Vanguard's broader entities likely remain, just reported differently. However, a superficial reading of 0% ownership could cause temporary concern if the context is missed.
• The Vanguard Group Investors: This realignment clarifies reporting responsibilities among Vanguard's internal entities.

Next Steps

• Certain Vanguard subsidiaries and/or business divisions will report beneficial ownership separately.

Key Dates

Keywords

Vir Biotechnology, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Realignment